Last reviewed · How we verify

NCT00821444

Phase 1 Study Of Ziprasidone Pharmacokinetics Of Reduced Food Effect Formulation B16 Under Fed And Fasting Conditions Compared To Commercial Geodon Capsules Under Fed Conditions In Healthy Subjects

Completed Phase 1 Last updated 18 February 2021
What this trial tests

Phase 1 trial testing ziprasidone in Healthy in 11 participants. Completed in 1 March 2009.

Timeline
1 January 2009
Primary endpoint
1 March 2009
1 March 2009

Quick facts

Lead sponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposebasic science
Enrollment11
Start date1 January 2009
Primary completion1 March 2009
Estimated completion1 March 2009
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full company profile →

Who can join

Adults 18 to 55, any sex, with Healthy. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

Commercial ziprasidone capsules show a large increase in bioavailability with food. The formulation tested in this study aims to reduce or eliminate that increase.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of ziprasidone

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Pfizer's Upjohn has merged with Mylan to form Viatris Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00821444.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing